drugset / Trial / NCT06026254
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
NaSingle-groupOpen-labelTreatment
Summary
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Timeline
- Start
- 2023-09-15
- Primary completion
- 2025-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMSA101 | Small molecule | — | Other |